Additionally, bepridil enhanced the cytotoxic effects of ibrutinib, a BTK inhibitor used for CLL treatment; however, the interaction between BCR and Notch1 pathways in CLL requires further studies to identify the subsets of patients who could benefit from this therapy [265,266]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.